Transplantation of bone marrow-derived stem cells: a promising therapy for stroke.
Stroke remains a major cause of death in the US and around the world. Over the last decade, stem cell therapy has been introduced as an experimental treatment for stroke. Transplantation of stem cells or progenitors into the injured site to replace the nonfunctional cells, and enhancement of proliferation or differentiation of endogenous stem or progenitor cells stand as the two major cell-based strategies. Potential sources of stem/progenitor cells for stroke include fetal neural stem cells, embryonic stem cells, neuroteratocarcinoma cells, umbilical cord blood-derived nonhematopoietic stem cells, and bone marrow-derived stem cells. The goal of this article is to provide an update on the preclinical use of bone marrow-derived stem cells with major emphasis on mesenchymal stem cells (MSCs) and multipotent adult progenitor cells (MAPCs) because they are currently most widely applied in experimental stroke studies and are now being phased into early clinical trials. The phenotypic features of MSCs and MAPCs, as well as their application in stroke, are described.
Tang
Yamei
Y
Department of Neurology, Medical College of Georgia, Augusta 30912-3200, USA.
Yasuhara
Takao
T
Hara
Koichi
K
Matsukawa
Noriyuki
N
Maki
Mina
M
Yu
Guolong
G
Xu
Lin
L
Hess
David C
DC
Borlongan
Cesario V
CV
D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology*; D006801:Humans; D039902:Multipotent Stem Cells / Q000166:cytology; D039904:Pluripotent Stem Cells / Q000166:cytology; D033581:Stem Cell Transplantation; D020521:Stroke / Q000628:therapy*